What's Happening?
Tandem Diabetes Care has received FDA clearance for its Control-IQ+ Automated Insulin Delivery Technology, specifically for use in managing type 1 diabetes during pregnancy. This approval is based on the CIRCUIT trial results, published in the Journal
of the American Medical Association, which demonstrated a 12.6% increase in time spent within the pregnancy glucose target range. This translates to approximately three additional hours per day in the target range compared to standard therapy. The technology is designed to make automated adjustments to basal insulin delivery, addressing the need for precise glucose management to prevent maternal and neonatal complications during pregnancy.
Why It's Important?
The FDA's clearance of Control-IQ+ technology marks a significant advancement in diabetes management for pregnant women with type 1 diabetes. This technology provides a more precise and automated approach to insulin delivery, which is crucial given the tighter glycemic targets required during pregnancy. The approval fills a critical gap in the diabetes technology market, offering a solution that can improve pregnancy outcomes and reduce the risk of complications. This development is likely to benefit healthcare providers and patients by offering a more reliable and effective tool for managing diabetes during pregnancy.
What's Next?
Following this approval, Tandem Diabetes Care plans to launch an educational campaign to prepare healthcare providers for integrating this technology into prenatal care. This initiative will begin at the American Diabetes Association Scientific Sessions in June 2026. The company aims to ensure that maternal-fetal medicine specialists and endocrinologists are well-equipped to use the Control-IQ+ system effectively. This educational effort reflects a broader commitment to improving diabetes management during pregnancy and could lead to wider adoption of automated insulin delivery systems in prenatal care.
